Shots

• The company has commenced P-I clinical study assessing its vaccine candidate vs PBO in 144 healthy adults- aged 18-59yrs- with two different dosages of the vaccine candidate- conducted in Jiangsu Province
• The study evaluates the safety- tolerance- and preliminary immunogenicity of Sinovac’s SARS-CoV-2 vaccine under which two-thirds of the volunteers will be vaccinated with the investigational vaccine while one-third of volunteers will be treated with PBO
• On April 13- 2020- the NMPA has approved P-I/II clinical study of its inactivated SARS-CoV-2 vaccine to evaluate the safety and immunogenicity of the vaccine

Click here to read full press release/ article | Ref: Business wire | Image: Behance

Related News: Dynavax Signs an Agreement with Sinovac to Develop a Vaccine for COVID-19